TY - JOUR
T1 - Toxicological evaluation of naringin-loaded nanocapsules in vitro and in vivo
AU - Budel, Renata Gancine
AU - da Silva, Denise Ajala
AU - Moreira, Michele Pereira
AU - Dalcin, Ana Júlia Figueiró
AU - da Silva, Aline Franzen
AU - Nazario, Luiza Reali
AU - Majolo, Julia Huppes
AU - Lopes, Leonardo Quintana Soares
AU - Santos, Roberto Christ Vianna
AU - Antunes Soares, Felix Alexandre
AU - da Silva, Rosane Souza
AU - Gomes, Patrícia
AU - Boeck, Carina Rodrigues
N1 - Copyright © 2019 Elsevier B.V. All rights reserved.
PY - 2020/4
Y1 - 2020/4
N2 - Naringin is a flavonoid widely known for its pharmacological properties, such as: anti-inflammatory and antioxidant ones, being an ally to avoid oxidative damage. Although naringin is an active easily found in citrus fruits, it has low bioavailability, biodistribution and also undergoes biotransformation in naringenin, limiting the described effects. The use of nanocapsules as drug carriers may increase solubility, improve biodistribution, impede the biotransformation thereof, and thus could improve the performance of naringin for use in treating neurological diseases. Therefore, the objective of this work is to produce a nanocapsule containing naringin, validate an analytical method by RP-HPLC to determination of the drug in nanoparticle and evaluate the toxicity. To that end, the blank nanocapsules (NB, without the drug) or naringin-loaded nanocapsules (NN) at the concentration of 2 mg/mL were prepared by interfacial deposition of the preformed polymer and the quantification of naringin by HPLC. Toxicity of the formulations was evaluated in vitro in rat hippocampal slices and in vivo models with C. elegans and Danio rerio (zebrafish). The analytical parameters evaluated (linearity, limit of detection and quantification, specificity, precision, accuracy and robustness) indicated adequate method to assay of naringin in nanocapsules by HPLC. There was no indication of toxicity by the nanocapsules in the evaluated biological assays.
AB - Naringin is a flavonoid widely known for its pharmacological properties, such as: anti-inflammatory and antioxidant ones, being an ally to avoid oxidative damage. Although naringin is an active easily found in citrus fruits, it has low bioavailability, biodistribution and also undergoes biotransformation in naringenin, limiting the described effects. The use of nanocapsules as drug carriers may increase solubility, improve biodistribution, impede the biotransformation thereof, and thus could improve the performance of naringin for use in treating neurological diseases. Therefore, the objective of this work is to produce a nanocapsule containing naringin, validate an analytical method by RP-HPLC to determination of the drug in nanoparticle and evaluate the toxicity. To that end, the blank nanocapsules (NB, without the drug) or naringin-loaded nanocapsules (NN) at the concentration of 2 mg/mL were prepared by interfacial deposition of the preformed polymer and the quantification of naringin by HPLC. Toxicity of the formulations was evaluated in vitro in rat hippocampal slices and in vivo models with C. elegans and Danio rerio (zebrafish). The analytical parameters evaluated (linearity, limit of detection and quantification, specificity, precision, accuracy and robustness) indicated adequate method to assay of naringin in nanocapsules by HPLC. There was no indication of toxicity by the nanocapsules in the evaluated biological assays.
KW - Animals
KW - Behavior, Animal
KW - Caenorhabditis elegans
KW - Flavanones/chemistry
KW - Models, Animal
KW - Nanocapsules/chemistry
KW - Rats
KW - Zebrafish
U2 - 10.1016/j.colsurfb.2019.110754
DO - 10.1016/j.colsurfb.2019.110754
M3 - Article
C2 - 31887647
SN - 0927-7765
VL - 188
JO - Colloids and Surfaces B: Biointerfaces
JF - Colloids and Surfaces B: Biointerfaces
M1 - 110754
ER -